AGEN – Agenus Inc.
Agenus Inc.AGEN
$3.32Name : Agenus Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $78,391,504.00
EPSttm : -11.02
Agenus Inc.
$3.32
3.77%$0.13Float Short %
12.79
Margin Of Safety %
Put/Call OI Ratio
0.16
EPS Next Q Diff
1.26
EPS Last/This Y
EPS This/Next Y
4.98
Price
3.33
Target Price
7.75
Analyst Recom
2.6
Performance Q
26.24
Relative Volume
0.49
Beta
1.19
Ticker: AGEN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | AGEN | 3.77 | 0.06 | 0.11 | 8892 |
| 2025-01-24 | AGEN | 3.56 | 0.08 | 0.12 | 9207 |
| 2025-01-27 | AGEN | 3.6 | 0.08 | 0.08 | 9278 |
| 2025-01-28 | AGEN | 3.57 | 0.08 | 0.23 | 10064 |
| 2025-01-29 | AGEN | 3.62 | 0.09 | 0.04 | 10084 |
| 2025-01-30 | AGEN | 3.54 | 0.08 | 0.33 | 11900 |
| 2025-01-31 | AGEN | 3.82 | 0.08 | 0.03 | 11921 |
| 2025-02-03 | AGEN | 3.51 | 0.08 | 0.44 | 13163 |
| 2025-02-04 | AGEN | 3.51 | 0.08 | 0.09 | 13442 |
| 2025-02-05 | AGEN | 3.91 | 0.09 | 0.31 | 13901 |
| 2025-02-06 | AGEN | 3.73 | 0.09 | 0.10 | 14012 |
| 2025-02-07 | AGEN | 3.5 | 0.09 | 6.50 | 14133 |
| 2025-02-10 | AGEN | 3.25 | 0.09 | 0.80 | 14155 |
| 2025-02-11 | AGEN | 3.22 | 0.09 | 1.59 | 14209 |
| 2025-02-12 | AGEN | 3.47 | 0.13 | 0.34 | 14877 |
| 2025-02-13 | AGEN | 3.51 | 0.13 | 10.35 | 15346 |
| 2025-02-14 | AGEN | 3.51 | 0.15 | 0.19 | 15511 |
| 2025-02-18 | AGEN | 3.51 | 0.14 | 4.29 | 15441 |
| 2025-02-19 | AGEN | 3.47 | 0.15 | 2.29 | 15498 |
| 2025-02-20 | AGEN | 3.44 | 0.16 | 0.45 | 15700 |
| 2025-02-21 | AGEN | 3.33 | 0.16 | 1.56 | 15634 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | AGEN | 3.76 | -1.5 | 73.4 | -12.17 |
| 2025-01-24 | AGEN | 3.56 | -1.5 | 74.6 | -12.17 |
| 2025-01-27 | AGEN | 3.60 | -1.5 | 73.7 | -12.17 |
| 2025-01-28 | AGEN | 3.57 | -1.5 | 73.8 | -12.17 |
| 2025-01-29 | AGEN | 3.62 | -1.5 | 73.5 | -12.17 |
| 2025-01-30 | AGEN | 3.54 | -1.5 | 74.0 | -12.17 |
| 2025-01-31 | AGEN | 3.78 | -1.5 | 72.9 | -12.17 |
| 2025-02-03 | AGEN | 3.51 | 2.2 | 74.9 | -12.17 |
| 2025-02-04 | AGEN | 3.50 | 2.2 | 73.9 | -12.17 |
| 2025-02-05 | AGEN | 3.89 | 2.2 | 72.3 | -12.17 |
| 2025-02-06 | AGEN | 3.73 | 2.2 | 74.4 | -12.17 |
| 2025-02-07 | AGEN | 3.51 | 2.2 | 74.7 | -12.17 |
| 2025-02-10 | AGEN | 3.23 | 2.2 | 74.9 | -12.17 |
| 2025-02-11 | AGEN | 3.21 | 2.2 | 73.9 | -12.17 |
| 2025-02-12 | AGEN | 3.46 | 2.2 | 72.8 | -12.17 |
| 2025-02-13 | AGEN | 3.50 | 2.2 | 73.7 | -12.17 |
| 2025-02-14 | AGEN | 3.51 | 2.2 | 73.8 | -12.17 |
| 2025-02-18 | AGEN | 3.52 | 2.2 | 73.8 | -12.17 |
| 2025-02-19 | AGEN | 3.48 | 2.2 | 73.9 | -12.17 |
| 2025-02-20 | AGEN | 3.45 | 2.2 | 73.9 | -12.17 |
| 2025-02-21 | AGEN | 3.33 | 2.2 | 74.3 | -12.17 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | AGEN | 0.00 | -4.02 | 13.21 |
| 2025-01-24 | AGEN | 0.00 | -4.02 | 13.21 |
| 2025-01-27 | AGEN | 0.00 | -2.97 | 13.21 |
| 2025-01-28 | AGEN | 0.00 | -2.97 | 13.14 |
| 2025-01-29 | AGEN | 0.00 | -2.97 | 13.14 |
| 2025-01-30 | AGEN | 0.00 | -2.97 | 13.14 |
| 2025-01-31 | AGEN | 0.00 | -2.97 | 13.14 |
| 2025-02-03 | AGEN | 0.00 | -2.92 | 13.15 |
| 2025-02-04 | AGEN | 0.00 | -2.92 | 13.15 |
| 2025-02-05 | AGEN | 0.00 | -2.92 | 13.15 |
| 2025-02-06 | AGEN | 0.00 | -2.92 | 13.15 |
| 2025-02-07 | AGEN | 0.00 | -2.92 | 13.15 |
| 2025-02-10 | AGEN | 0.00 | -2.85 | 13.15 |
| 2025-02-11 | AGEN | 0.00 | -2.85 | 13.15 |
| 2025-02-12 | AGEN | 0.00 | -2.85 | 13.10 |
| 2025-02-13 | AGEN | 0.00 | -2.85 | 13.10 |
| 2025-02-14 | AGEN | 0.00 | -2.85 | 13.10 |
| 2025-02-18 | AGEN | 0.00 | -2.41 | 13.24 |
| 2025-02-19 | AGEN | 0.00 | -2.41 | 12.79 |
| 2025-02-20 | AGEN | 0.00 | -2.41 | 12.79 |
| 2025-02-21 | AGEN | 0.00 | -2.41 | 12.79 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-3.17
Avg. EPS Est. Current Quarter
-2.64
Avg. EPS Est. Next Quarter
-1.91
Insider Transactions
Institutional Transactions
-2.41
Beta
1.19
Average Sales Estimate Current Quarter
31
Average Sales Estimate Next Quarter
16
Fair Value
Quality Score
51
Growth Score
39
Sentiment Score
21
Actual DrawDown %
97.5
Max Drawdown 5-Year %
-98
Target Price
7.75
P/E
Forward P/E
PEG
P/S
0.49
P/B
P/Free Cash Flow
EPS
-11
Average EPS Est. Cur. Y
-12.17
EPS Next Y. (Est.)
-7.19
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-142.03
Relative Volume
0.49
Return on Equity vs Sector %
58.7
Return on Equity vs Industry %
74.3
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
-1.29
EBIT Estimation
74.3
Agenus Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 389
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
stock quote shares AGEN – Agenus Inc. Stock Price stock today
news today AGEN – Agenus Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AGEN – Agenus Inc. yahoo finance google finance
stock history AGEN – Agenus Inc. invest stock market
stock prices AGEN premarket after hours
ticker AGEN fair value insiders trading